Paper40284530
Thymoquinone Enhances Doxorubicin Efficacy via RAS/RAF Pathway Modulation in Ovarian Adenocarcinoma.
Toprak V and 5 others. Pharmaceutics, 2025. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Thymoquinone Enhances Doxorubicin Efficacy via RAS/RAF Pathway Modulation in Ovarian Adenocarcinoma. Papers, record 40284530. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40284530
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Thymoquinone Enhances Doxorubicin Efficacy via RAS/RAF Pathway Modulation in Ovarian Adenocarcinoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34484227 | Hallmarks of Cancers: Primary Antibody Deficiency Versus Other Inborn Errors of Immunity. | Front Immunol | 2021 | https://conductscience.org/library/papers/34484227 | PubMed |
| 2 | 23744360 | Redox cycling of endogenous copper by thymoquinone leads to ROS-mediated DNA breakage and consequent cell death: putative anticancer mechanism of antioxidants. | Cell Death Dis | 2013 | https://conductscience.org/library/papers/23744360 | PubMed |
| 3 | 35437842 | Suppressive effects of thymoquinone on the initiation stage of diethylnitrosamine hepatocarcinogenesis in rats. | J Biochem Mol Toxicol | 2022 | https://conductscience.org/library/papers/35437842 | PubMed |
| 4 | 38248312 | Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer. | Curr Issues Mol Biol | 2023 | https://conductscience.org/library/papers/38248312 | PubMed |
| 5 | 32297580 | Thymoquinone, an Active Compound of Nigella sativa: Role in Prevention and Treatment of Cancer. | Curr Pharm Biotechnol | 2020 | https://conductscience.org/library/papers/32297580 | PubMed |
| 6 | 31099893 | Epithelial ovarian cancer: Evolution of management in the era of precision medicine. | CA Cancer J Clin | 2019 | https://conductscience.org/library/papers/31099893 | PubMed |
| 7 | 37909496 | Telomerase inhibitors TMPyP4 and thymoquinone decreased cell proliferation and induced cell death in the non-small cell lung cancer cell line LC-HK2, modifying the pattern of focal adhesion. | Braz J Med Biol Res | 2023 | https://conductscience.org/library/papers/37909496 | PubMed |
| 8 | 27798862 | Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies. | Anticancer Res | 2016 | https://conductscience.org/library/papers/27798862 | PubMed |
| 9 | 35011457 | Insights into the Protective Effects of Thymoquinone against Toxicities Induced by Chemotherapeutic Agents. | Molecules | 2021 | https://conductscience.org/library/papers/35011457 | PubMed |
| 10 | 38087345 | Potential anticancer properties and mechanisms of thymoquinone in colorectal cancer. | Cancer Cell Int | 2023 | https://conductscience.org/library/papers/38087345 | PubMed |
| 11 | 36432484 | Anticancer Effects of Thymoquinone through the Antioxidant Activity, Upregulation of Nrf2, and Downregulation of PD-L1 in Triple-Negative Breast Cancer Cells. | Nutrients | 2022 | https://conductscience.org/library/papers/36432484 | PubMed |
| 12 | 38105263 | Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/38105263 | PubMed |
| 13 | 31433961 | Thymoquinone induces apoptosis of human epidermoid carcinoma A431 cells through ROS-mediated suppression of STAT3. | Chem Biol Interact | 2019 | https://conductscience.org/library/papers/31433961 | PubMed |
| 14 | 35713779 | Programmed cell death detection methods: a systematic review and a categorical comparison. | Apoptosis | 2022 | https://conductscience.org/library/papers/35713779 | PubMed |
| 15 | 33923474 | Thymoquinone, as a Novel Therapeutic Candidate of Cancers. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/33923474 | PubMed |
| 16 | 38510007 | Immune stimulatory effect of Nigella sativa in healthy animal models: A systematic review and meta-analysis. | Heliyon | 2024 | https://conductscience.org/library/papers/38510007 | PubMed |
| 17 | 31885471 | Thymoquinone (2-Isoprpyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/anticancer agent: Chemistry and biological effects. | Saudi Pharm J | 2019 | https://conductscience.org/library/papers/31885471 | PubMed |
| 18 | 32901987 | Thymoquinone inhibits the proliferation and invasion of esophageal cancer cells by disrupting the AKT/GSK-3β/Wnt signaling pathway via PTEN upregulation. | Phytother Res | 2020 | https://conductscience.org/library/papers/32901987 | PubMed |
| 19 | 32798788 | Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer. | Eur J Med Chem | 2020 | https://conductscience.org/library/papers/32798788 | PubMed |
| 20 | 28881699 | Thymoquinone, as an anticancer molecule: from basic research to clinical investigation. | Oncotarget | 2017 | https://conductscience.org/library/papers/28881699 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42793131 | Epigallocatechin Gallate Modulates the Cellular Response to Doxorubicin in HeLa Cervical Cancer Cells. | Biomolecules | 2026 | https://conductscience.org/library/papers/42793131 | PubMed |
| 42792721 | Cytotoxic, Drug-Interaction, and Apoptosis-Associated Effects of β-Boswellic Acid and Doxorubicin in Murine 4T1 TNBC-like Cells. | Biomedicines | 2026 | https://conductscience.org/library/papers/42792721 | PubMed |
| 42792719 | Rosmarinic Acid Enhances Doxorubicin Activity in MDA-MB-231 Cells: Associations with Intracellular Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis. | Biomedicines | 2026 | https://conductscience.org/library/papers/42792719 | PubMed |
| 42653655 | Thymoquinone Potentiates Docetaxel-Induced Antitumor Activity with the Involvement of ROS and PI3K/AKT Pathway Modulation in Triple-Negative Breast Cancer Cells. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42653655 | PubMed |
| 42351769 | Integrated Evaluation of the Synergistic Antitumor Effects of Thymoquinone and Docetaxel in Ovarian Cancer Cells: Apoptosis, Oxidative Stress, and 3D Spheroid Responses. | Biomedicines | 2026 | https://conductscience.org/library/papers/42351769 | PubMed |
| 42351676 | Synergistic Effects of Doxorubicin and Quercetin on ROS-Associated Apoptosis and EGFR/FOXP3 Modulation in OVCAR3 Cells. | Biomedicines | 2026 | https://conductscience.org/library/papers/42351676 | PubMed |
| 42196484 | A Functional Evaluation of Resveratrol-Paclitaxel Combination Reveals Enhanced Apoptotic Responses in HeLa Cells. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196484 | PubMed |
| 42075801 | Quercetin Sensitizes Retinoblastoma Cells to Mitomycin C Through Transcriptional Modulation of p53-Regulated Apoptotic Genes: A Preclinical Study. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42075801 | PubMed |
| 41749873 | Synergistic Antitumor Activity of Curcumin and the PARP1 Inhibitor PJ34 in Platinum-Sensitive and Resistant Ovarian Cancer Cells. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41749873 | PubMed |
| 41596149 | Molecular Insights into the Synergistic Anticancer and Oxidative Stress-Modulating Activity of Quercetin and Gemcitabine. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/41596149 | PubMed |
| 41020906 | Synergistic Induction of Apoptosis by Boswellic Acid and Cisplatin in A549 Lung Cancer Cells Through NF-κB Modulation and p53 Pathway Activation. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/41020906 | PubMed |
| 41010990 | Combined Hesperidin and Gemcitabine Therapy Modulates Apoptosis and Angiogenesis Pathways in ISHIKAWA Human Endometrial Adenocarcinoma Cells. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/41010990 | PubMed |
| 40870392 | PI3K/Akt1 Pathway Suppression by Quercetin-Doxorubicin Combination in Osteosarcoma Cell Line (MG-63 Cells). | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/40870392 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BAX | 581 | PubTator's text mining | https://conductscience.org/library/genes/581 | NCBI Gene |
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| ZHX2 | 22882 | PubTator's text mining | https://conductscience.org/library/genes/22882 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40284530
GET https://conductscience.org/api/papers/v1/40284530/references?page=2